Similarly, in TILs from patients with ovarian cancer, simultaneous LAG-3 and PD-1 blockade restores responsiveness of NY-ESO-1-specific LAG3+/PD-1+ CD8+ T cells to a greater extent than blockade of each coinhibitory receptor alone. Here, LAG3 is linked to ovarian cancer.